Vutiglabridin: a new candidate from Korea, tested in untreated patients
A derivative of a liquorice compound is meant to protect the power plants of nerve cells. A small phase 2a trial in untreated patients shows a first signal.
Updated: 12 November 2026

It is rare for a new drug to be tested in exactly the group I belong to: people with Parkinson's who do not take Parkinson's medication. That was the case with vutiglabridin. That is why I took a close look at the data presented in October 2026 at the international Parkinson's congress in Seoul.
What vutiglabridin is
Vutiglabridin, also called HSG4112 during development, comes from the South Korean company Glaceum. It is a lab-made derivative of glabridin, a compound found in liquorice root. The drug is swallowed as a tablet and reaches the brain.
It targets two of the body's own protective enzymes, the paraoxonases PON1 and PON2. PON2 in particular sits in the mitochondria, the power plants of the cell, and protects them from oxidative stress. In mouse models of Parkinson's, vutiglabridin protected the dopamine cells. When PON2 was reduced in the animals, this protection disappeared. This suggests that the drug really does work through this pathway. This preliminary work was published in December 2025 in the journal Molecular Neurodegeneration (abstract).
The substance was originally developed as a metabolic drug against obesity.
The trial
The phase 2a trial ran at nine centers in South Korea. 99 people were randomly assigned to three groups: 400 mg daily, 800 mg daily or placebo. Treatment lasted 24 weeks, followed by four weeks without the drug (trial registry NCT06329141).
Only people whose diagnosis was no more than two years old and who were not taking Parkinson's medication were included. Cases in which tremor is the main symptom were excluded.
The change in the motor part of the MDS-UPDRS was measured, the same scale used to document my own course. Lower values mean fewer symptoms. After 24 weeks the picture was:
- 800 mg: improvement of 2.83 points
- 400 mg: improvement of 1.37 points
- Placebo: worsening of 0.73 points
The difference between the high dose and placebo is 3.56 points and was statistically significant (p = 0.03). That the higher dose worked better than the low one fits the picture. There were no serious side effects attributed to the drug.
Why I remain cautious
The result is encouraging, but I do not want to make it bigger than it is. Four points hold me back.
First, the result is based on 77 of the 99 participants. Only those who completed the trial as planned were analyzed. Almost a quarter are missing. The stricter analysis of all randomized participants has not been shown so far. With such small groups, that can make the difference.
Second, the effect is small. The threshold at which patients notice a change in everyday life at all is considered to be just over three points. 3.56 points is only slightly above it.
Third, the data that would show whether the disease is really being slowed or only symptoms relieved are missing, such as imaging of the dopamine cells over time or a blood marker for nerve cell damage. What happened in the four weeks after stopping the drug has not been reported either. That would be particularly revealing: if the benefit persists, it points to protection of the cells. If it disappears, it was more likely a symptomatic effect.
Fourth, this is a congress presentation, not a peer-reviewed publication. So far nobody outside the trial can check the full data.
How quickly a promising small study can flip in a large one was shown this year by the NOPARK trial of nicotinamide riboside. There, too, there was a plausible mechanism and good early data. In the large trial with 410 participants, the treated group ended up doing worse than placebo.
Is it available?
No. Vutiglabridin is not approved anywhere in the world, neither for Parkinson's nor for obesity. There is no legal way for patients to get it other than by taking part in a trial.
Online, suppliers of laboratory chemicals offer the substance, explicitly for research purposes only. I clearly advise against it. This material is not made for humans, nobody guarantees purity or content, and the trial dose of 800 mg daily over months could not be reproduced safely or sensibly with it.
Liquorice root or liquorice sweets are no substitute either. Vutiglabridin is a deliberately modified substance with different properties from natural glabridin. Liquorice also contains glycyrrhizin, which in larger amounts raises blood pressure and lowers potassium levels.
My conclusion
Vutiglabridin goes on my watch list, near the top. A new mechanism, a tablet, good tolerability and a result in untreated patients are more than most candidates can show. My neurologist also finds the approach very interesting.
For me personally, nothing changes for now. I could not take part in a trial with the same conditions, because my diagnosis is more than two years old. I am waiting for three things: the full publication with the analysis of all participants, the data on imaging and on the period after stopping the drug, and a larger follow-up trial. Only then can we say whether this candidate can become a medicine.
Sources
- NeurologyLive: Metabolic agent vutiglabridin improves motor scores in early-stage study (7 October 2026)
- ClinicalTrials.gov: trial NCT06329141
- Molecular Neurodegeneration 2025: vutiglabridin as a PON2 modulator in Parkinson's models
Note: This article describes my personal view and is not medical advice. Vutiglabridin is an investigational drug and is not approved anywhere.